Dynamic change of the systemic immune inflammation index is a risk factor for patients with oropharyngeal cancer: a case control study and an additional HPV-status subgroup analysis

作者全名："Gan, XiaoChuan; Gou, QiTao; Zhu, Jing; Zhang, Tao"

作者地址："[Gan, XiaoChuan; Gou, QiTao; Zhu, Jing; Zhang, Tao] Chongqing Med Univ, Dept Oncol, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China"

通信作者："Zhu, J; Zhang, T (通讯作者)，Chongqing Med Univ, Dept Oncol, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China."

来源：EUROPEAN JOURNAL OF MEDICAL RESEARCH

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001011233700001

JCR分区：Q2

影响因子：2.8

年份：2023

卷号：28

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：Dynamic change; Inflammation; Prognosis; Human papillomavirus; Serial monitoring; Oropharyngeal cancer

摘要："BackgroundThe study aimed to analyze the relationship between the dynamic systemic immune inflammation index (SII), human papillomavirus (HPV) infection, and the prognosis of oropharyngeal cancer patients.MethodWe retrospectively obtained the data for 131 patients treated with curative treatments and calculated their SII values based on results acquired approximately 9 months after the first treatment. The entire cohort was divided into groups according to dynamic SII and HPV infection, and their prognoses were compared.ResultsThe high SII group, particularly the persistently high SII group, had a poor prognosis, and static SII levels cannot fully reflect the prognosis of patients with oropharyngeal cancer. In HPV- patients, unfavorable dynamic SII and the site of tumor locating at the tongue base were all significantly associated with decreased disease-free survival. In contrast, no characteristic was presented as a poor prognostic factor for disease-free or overall survival in HPV+ patients.ConclusionDynamic SII values are more comprehensive prognostic indicators for oropharyngeal cancer patients, particularly HPV- patients. It could imply that an HPV- oropharyngeal cancer patient who experienced unfavorable dynamic changes in SII should receive more frequent tests or more advanced therapies."

基金机构：　

基金资助正文：